This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $3,785.80 firm fixed-price delivery order is for the supply of Nucala 100 mg/mL auto-injectors. The contract has an ultimate completion date of December 13, 2024 and is not associated with any set-aside designation.
DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This positioning as a key supplier in the federal pharmaceutical supply chain allows DMS Pharmaceutical Group to provide direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.
Generated 3/13/25, 9:50 AM